Source: Eur Respir J 2002; 19: 257-266
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Melis M., Siena L., Pace E., Gjomarkaj M., Profita M., Pirazzoli A., Todaro M., Stassi G., Bonsignore G., Vignola A.M.. Fluticasone induces apoptosis in peripheral T-lymphocytes: a comparison between asthmatic and normal subjects. Eur Respir J 2002; 19: 257-266

Member's Comments

No comment yet.

Related content which might interest you: Low doses of inhaled fluticasone propionate induce sputum eosinophil apoptosis and inhibit IL-5 release in naive symptomatic asthmatics (FLIC19) Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 Combined treatment with fluticasone plus salmeterol protects against allergen induced asthmatic responses and subsequent increase in sputum eosinophils Source: Eur Respir J 2002; 20: Suppl. 38, 189s Year: 2002 Symptoms, induced sputum eosinophil percentages and treatment with salmeterol or fluticasone in mild asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 336s Year: 2001 A comparison of suplatast tosilate, a Th2 cytokine inhibitor, and inhaled fluticasone propionate for airway inflammation in mild asthma Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002 Eosinophil apoptosis in induced sputum (IS) from patients with mild symptomatic asthma during treatment with Fluticasone propionate (FP) Source: Eur Respir J 2001; 18: Suppl. 33, 337s Year: 2001 Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study Source: Eur Respir J 2002; 20: 1378-1385 Year: 2002 Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression Source: Eur Respir J 2001; 18: 139-145 Year: 2001 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008 The effects of treatment with fluticasone propionate alone and combination with salmeterol on asthma control and airway inflammation Source: Eur Respir J 2003; 22: Suppl. 45, 287s Year: 2003 Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006 The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004 Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats Source: Eur Respir J 2002; 20: 873-879 Year: 2002 Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma Source: Eur Respir J 2002; 20: 853-858 Year: 2002 Proliferation is not increased in airway myofibroblasts isolated from asthmatics Source: Eur Respir J 2008; 32: 362-371 Year: 2008 Salmeterol/fluticasone propionate combination (SFC) improves airways hyperresponsiveness (AHR), lung function and symptoms in adult patients with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 262s Year: 2004 Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002 Fluticasone does not add to the salmeterol effect on pig-dust induced inflammation in the lower airways Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006 Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002 Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004